Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1450717
European Journal of Endocrinology, Vol 145, Issue 6, 717-726
Copyright © 2001 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cozzi, R
Right arrow Articles by Attanasio, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cozzi, R
Right arrow Articles by Attanasio, R
Articles

Failure of radiotherapy in acromegaly

R Cozzi, M Barausse, D Asnaghi, D Dallabonzana, S Lodrini, and R Attanasio

Division of Endocrinology, Niguarda Hospital, Neurological Institute Carlo Besta, Milan, Italy. renatocozzi@tiscalinet.it

BACKGROUND: Recent data has raised skepticism regarding the long-term effectiveness of radiotherapy (RxT) in acromegaly and its role as an ancillary tool to neurosurgery (Tx). PATIENTS: We evaluated 72 acromegalic patients previously submitted to RxT. Data were discarded in 23 patients, who were lost to follow-up, operated on after RxT or irradiated with techniques different from external conventional fractionated RxT. Among the remaining 49 (five with mixed GH-prolactin adenoma), 34 were irradiated after surgical failure and 15 as primary treatment. A second cycle of RxT was administered in two. RESULTS: (i) GH/IGF-I. After a median follow-up of 14 years (range 3-41), normal age-matched IGF-I levels were reached in eight patients (16%) after 10 years, and GH levels <2.5 microg/l in six (12%) after 9 years. The rate of persistently pathological hormonal levels was still 90% at 25 years. All patients with GH/IGF-I normalization had undergone irradiation without any antisecretory drug. Neither basal GH nor tumor size affected the outcome of RxT. In three patients (6%) a relapse/worsening occurred. (ii) Tumor size. Tumor shrank after 8.5 years in 24 patients (49%), in nine of whom during GH-suppressive treatment. Tumor shrinkage was not predictive of hormonal normalization. (iii) Side-effects. Hypopituitarism was diagnosed in four patients (selective in three and global in one) and GH deficiency in one. Three patients had neurological side-effects and meningioma was shown in two patients. CONCLUSION: RxT is unable to cure acromegaly, because it seldom achieves hormonal normalization even after a very prolonged follow-up. Concomitant antisecretory treatment seems to counteract its effects. RxT can still play a role in those patients with large tumor remnants, because of its capacity to shrink tumor size.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Losa, L. Gioia, P. Picozzi, A. Franzin, M. Valle, M. Giovanelli, and P. Mortini
The Role of Stereotactic Radiotherapy in Patients with Growth Hormone-Secreting Pituitary Adenoma
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2546 - 2552.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E. O. Vik-Mo, M. Oksnes, P.-H. Pedersen, T. Wentzel-Larsen, E. Rodahl, F. Thorsen, T. Schreiner, S. Aanderud, and M. Lund-Johansen
Gamma knife stereotactic radiosurgery for acromegaly
Eur. J. Endocrinol., September 1, 2007; 157(3): 255 - 263.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, and G. Pagani
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1397 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Animal Hospital AssociationHome page
C. A. Hurty and B. Flatland
Feline Acromegaly: A Review of the Syndrome
J. Am. Anim. Hosp. Assoc., September 1, 2005; 41(5): 292 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G M Besser, P Burman, and A F Daly
Predictors and rates of treatment-resistant tumor growth in acromegaly
Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Attanasio, R. Baldelli, R. Pivonello, S. Grottoli, L. Bocca, V. Gasco, M. Giusti, G. Tamburrano, A. Colao, and R. Cozzi
Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5258 - 5265.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Cozzi, R. Attanasio, M. Montini, G. Pagani, G. Lasio, S. Lodrini, M. Barausse, M. Albizzi, D. Dallabonzana, and A. M. Pedroncelli
Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3090 - 3098.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Attanasio, P. Epaminonda, E. Motti, E. Giugni, L. Ventrella, R. Cozzi, M. Farabola, P. Loli, P. Beck-Peccoz, and M. Arosio
Gamma-Knife Radiosurgery in Acromegaly: A 4-Year Follow-Up Study
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3105 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
Z Merza
Modern treatment of acromegaly
Postgrad. Med. J., April 1, 2003; 79(930): 189 - 194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 European Society of Endocrinology.